RxDoctor Payments DataLook up a doctor →

Matthew Jacobson, MD

Internal Medicine · Newark, DENPI 1346385507

Payments from drug & device makers

$10,082in general payments, 2019–2025

Across 621 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • GSK$1K
  • Pfizer$690
  • Lilly USA, LLC$562
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,064100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,082 in reported general payments places this provider in the 95th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$240,492
Medicare patients
567
Services billed
2,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$225,352
OzempicSemaglutide82$144,300
EliquisApixaban98$131,691
JanuviaSitagliptin Phosphate78$101,356
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$85,689
MounjaroTirzepatide50$54,630
FarxigaDapagliflozin Propanediol38$53,039
XareltoRivaroxaban39$53,006
TradjentaLinagliptin41$44,603
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$30,648
RybelsusSemaglutide17$24,921
MyrbetriqMirabegron21$24,087
TrulicityDulaglutide19$23,595
JanumetSitagliptin Phos/Metformin Hcl14$16,721
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$16,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$402$278,197223 claims
Novo NordiskOzempic, Rybelsus$1,524$169,22199 claims
PfizerEliquis$690$131,69198 claims
MerckJanuvia, Janumet, Janumet Xr$183$130,497106 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,013$116,33678 claims
Lilly USA, LLCMounjaro, Trulicity$562$78,22569 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,275$69,07455 claims
Johnson & JohnsonXarelto$30$53,00639 claims
Astellas Pharma US IncMyrbetriq$489$24,08721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →